Definium Therapeutics Reports Positive Phase 3 GAD Results
NEW YORK, August 12, 2026 Definium Therapeutics, Inc. announced positive topline results from the Phase 3 Voyage study evaluating...
MSA
Advertisement
Alterity Expands ATH434 Potential in Neurodegenerative Disease
MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026 Alterity Therapeutics Limited announced that the U.S. Patent and Trademark...
Tiziana Life Sciences Reports Positive Foralumab Data in Third MSA Patient
BOSTON, July 31, 2026 Tiziana Life Sciences announced new quantitative PET imaging results from the third patient with Multiple...
CORE Biomedicine Secures $21M Series A Funding
BOSTON, TOKYO and SUZHOU, July 28, 2026 CORE Biomedicine, a biotechnology company advancing lineage-based precision oncology therapeutics, has announced...
Co-Diagnostics Advances Ebola Testing Innovation Globally
SALT LAKE CITY, July 28, 2026 Co-Diagnostics, Inc. has announced two significant milestones that strengthen global preparedness against Ebola...
Advertisements
Dasher Neuroscience Advances YA-101 Phase 2 Trial
TAIPEI, July 28, 2026 Dasher Neuroscience Holdings Inc. has successfully completed patient enrollment in its global Phase 2 clinical...
Advertisement
